文献速递类风湿关节炎

阿巴西普在临床前期类风湿关节炎中的疗效与安全性:随机对照试验的系统综述与Meta分析

Efficacy and safety of abatacept in preclinical rheumatoid arthritis: A systematic review and meta-analysis of randomized controlled trials.
PubMed 文献 · Semin Arthritis Rheum · 2024-10-04

该系统综述与Meta分析纳入3项随机对照试验共367例临床前期类风湿关节炎高危参与者,方法遵循Cochrane手册与PRISMA声明。结果显示阿巴西普较安慰剂显著降低发展为类风湿关节炎的风险(RR 0.67,95%CI 0.51-0.89,P=0.006),并改善压痛关节计数与功能残疾,安全性方面感染、恶性肿瘤及因不良事件停药无显著差异。

要点

  • 阿巴西普较安慰剂显著降低临床前期高危人群发展为类风湿关节炎的风险(RR 0.67,95%CI 0.51-0.89,P=0.006)。
  • 阿巴西普改善压痛关节计数(SMD -0.40,95%CI -0.63至-0.18,P=0.0004)和功能残疾(SMD -1.51,95%CI -1.91至-1.11,P<0.00001),疼痛无显著差异。
  • 感染、恶性肿瘤及因不良事件停药在阿巴西普与安慰剂组间无显著差异。

核心结论

  • 阿巴西普是减缓临床前期类风湿关节炎高危人群疾病发展的有前景的治疗选择,且安全性良好。
  • 需要延长随访期的进一步研究来验证这些发现并提供更充分的数据。

研究设计与样本

  • 系统综述与Meta分析,纳入3项随机对照试验,共367例临床前期类风湿关节炎高危参与者。
  • 研究遵循Cochrane干预系统综述手册与PRISMA声明的程序。

主要发现

  • 阿巴西普较安慰剂显著降低发展为类风湿关节炎的风险(RR 0.67,95%CI 0.51-0.89,P=0.006)。
  • 阿巴西普改善压痛关节计数(SMD -0.40,95%CI -0.63至-0.18,P=0.0004)。
  • 阿巴西普显著减少功能残疾(SMD -1.51,95%CI -1.91至-1.11,P<0.00001)。
  • 疼痛减轻方面未观察到显著差异。
  • 安全性分析显示阿巴西普组与安慰剂组在感染、恶性肿瘤或因不良事件停药的发生上无显著差异。

局限性

  • 需要延长随访期的进一步研究来验证这些发现并提供更充分的数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Abatacept is a biological DMARD that has been used for the treatment of rheumatoid arthritis. However, the literature on its use in preclinical Rheumatoid arthritis (RA) is limited. We conducted this meta-analysis to evaluate the safety and efficacy of abatacept in preclinical RA. STUDY DESIGN: This meta-analysis intends to assess the effectiveness and safety of abatacept in persons who are at a high risk of developing rheumatoid arthritis (RA) during the pre-clinical phase. The analysis comprises of three randomized controlled trials (RCTs) involving atotal of 367 participants. The study follows the procedures specified in the Cochrane Handbook for Systematic Reviews of Interventions and the PRISMA statemen RESULTS: The meta-analysis found that abatacept significantly reduced the risk of developing RA compared to placebo (RR: 0.67; 95 % CI: 0.51 to 0.89; P = 0.006) and improved tender joint count (SMD: -0.40; 95 % CI: -0.63 to -0.18; P = 0.0004). Additionally, abatacept demonstrated a significant reduction in functional disability (SMD: -1.51; 95 % CI: -1.91 to -1.11; P < 0.00001), though no significant difference was observed in pain reduction. Safety analysis revealed no significant differences in the occurrence of infections, malignancy, or discontinuation due to adverse events between the abatacept and placebo groups. CONCLUSION: Abatacept is a promising treatment option for slowing down the development of RA in people who are at high risk. It has a positive safety profile. Additional studies with extended follow-up periods are required to validate these findings and offer more substantial data.

来源:Semin Arthritis Rheum,查看原文。版权归原作者所有。

引用

  1. Asif M, Asif A, Rahman UA, et al. Efficacy and safety of abatacept in preclinical rheumatoid arthritis: A systematic review and meta-analysis of randomized controlled trials. Semin Arthritis Rheum. 2024. PMID: 39393109. doi:10.1016/j.semarthrit.2024.152562

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。